Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE, for potential U.S. FDA New Drug Application in 2028 1,2,3 -